| Nesiritide | acute heart failure, in all type of patients | vs control | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | hospitalisation for heart failure | no data | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| NSGET (comparative trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | usual care | acutely decompensated heart failure requiring invasive monitoring
|
|
| Nesiritide | acute heart failure, in all type of patients | vs placebo | NS | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.48 [0.29 7.68] | p=1.00 | 0 | 127 | 1 | NSGET (efficacy trial), | | hospitalisation for heart failure | no data | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| NSGET (efficacy trial), 2000 | nesiritide(0.015 and 0.030 microg/kg/min | placebo | acutely decompensated heart failure requiring invasive monitoring | | VMAC (intravenous neseritide), 2002 | intravenous nesiritidefor 3 hours | placebo | acutely decompensated heart failure requiring hospitalization |
|
| Nesiritide | acute heart failure, in all type of patients | vs dobutamine | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | hospitalisation for heart failure | no data | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| PRECEDENT, 2002 | nesiritide(0.015 or 0.03 microg/kg/min) | Dobutamine (> or =5 microg/kg/min) | Symptomatic, Decompensated CHF |
|
| Nesiritide | acute heart failure, in all type of patients | vs nitroglycerin | NS | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 1.56 [0.76 3.19] | p=1.00 | 0 | 498 | 1 | VMAC (24h), | | hospitalisation for heart failure | no data | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| VMAC (24h), 2002 | nesiritideinfusion for 24 hours | nitroglycerin | acutely decompensated heart failure requiring hospitalization |
|
